Low-dose naltrexone for pruritus in systemic sclerosis

Tracy Frech, Kirsten Novak, Monica P Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, Allen D Sawitzke, Tracy Frech, Kirsten Novak, Monica P Revelo, Maureen Murtaugh, Boaz Markewitz, Nathan Hatton, Mary Beth Scholand, Edward Frech, David Markewitz, Allen D Sawitzke

Abstract

Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.

Figures

Figure 1
Figure 1
Biopsy specimens from patient 1: H&E-stained section shows moderate perivascular and periadnexal inflammation and thickening of dermal collagen (20X). There are several mast cells in perivascular, interstitial, and periadnexal distribution with granular-appearing cytoplasm (IHC mast cell tryptase 20X).
Figure 2
Figure 2
Biopsy specimens from patient 3: H&E-stained section shows scant perivascular inflammation and thickening of dermal collagen (20X). There are scattered mast cells in perivascular and interstitial distribution with granular-appearing cytoplasm (IHC mast cell tryptase 20X).

References

    1. Weisshaar E, Kucenic MJ, Fleischer AB., Jr. Pruritus: a review. Acta Dermato-Venereologica, Supplement. 2003;(213):5–32.
    1. Steen VD. Clinical manifestations of systemic sclerosis. Seminars in Cutaneous Medicine and Surgery. 1998;17(1):48–54.
    1. Razykov I, Thombs BD, Hudson M, Bassel M, Baron M. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis and Rheumatism. 2009;61(12):1765–1770.
    1. Verhoeven EW, de Klerk S, Kraaimaat FW, van de Kerkhof PCM, de Jong EM, Evers AWM. Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review. Acta Dermato-Venereologica. 2008;88(3):211–218.
    1. Jacobsen S, Halberg P, Ullman S, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. British Journal of Rheumatology. 1998;37(1):39–45.
    1. Cash WJ, McCance DR, Young IS, et al. Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk. Hepatology Research. 2010;40(11):1098–1106.
    1. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet Journal of Rare Diseases. 2008;3(1, article 1)
    1. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Medicine. 2009;10(4):663–672.
    1. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis. 2008;14(8):1076–1083.
    1. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. American Journal of Gastroenterology. 2007;102(4):820–828.
    1. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM. 2002;95(8):547–552.
    1. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4) European Journal of Neuroscience. 2008;28(1):20–29.
    1. San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. Neuroscience Letters. 2006;403(3):276–279.
    1. Masi AT, Rodnan GP, Medsger TA. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Arthritis and Rheumatism. 1980;23(5):581–590.
    1. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain. 1990;41(2):139–150.
    1. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosomatic Medicine. 1994;56(1):36–40.
    1. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis and Rheumatism. 2009;61(9):1257–1263.
    1. Khanna D, Hays RD, Park GS, et al. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis and Rheumatism. 2007;57(7):1280–1286.
    1. Bodukam V, Hays RD, Maranian P, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology. 2011;50(2):330–334.
    1. Steen VD, Medsger TA., Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis and Rheumatism. 1998;41(9):1613–1619.
    1. Khanna D, Furst DE, Hays RD, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Annals of the Rheumatic Diseases. 2006;65(10):1325–1329.
    1. Ständer S, Raap U, Weisshaar E, et al. Pathogenese des Pruritus. Journal of the German Society of Dermatology. 2011;9(6):456–463.
    1. El-Baalbaki G, Razykov I, Hudson M, Bassel M, Baron M, Thombs BD. Association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care and Research. 2010;62(10):1489–1495.
    1. Rashtak S, Pittelkow M. Skin involvement in systemic autoimmune diseases. Current Directions in Autoimmunity. 2008;10:344–358.
    1. Wiedermann CJ, Sacerdote P, Propst A, et al. Decreased β-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn’s disease. Brain, Behavior and Immunity. 1994;8(3):261–269.
    1. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis. 2010;16(8):964–969.
    1. Frieri M. Systemic sclerosis. The role of the mast cell and cytokines. Annals of Allergy. 1992;69(5):385–392.
    1. Claman HN. On scleroderma: mast cells, endothelial cells, and fibroblasts. Journal of the American Medical Association. 1989;262(9):1206–1209.
    1. Walker MM, Warwick A, Ung C, Talley NJ. The role of eosinophils and mast cells in intestinal functional disease. Current Gastroenterology Reports. 2011;13(4):323–330.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren